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Despite recent efforts to reduce cardiovascular disease risk by dietary intervention (1), 
few markers are useful to assess the efficiency and progress of this. Circulating levels of 
trimethylamine N-oxide (TMAO) are associated with poor outcomes of cardiovascular disease 
(2-6). TMAO is generated via hepatic flavin monooxygenase 3 (FMO3) mediated oxidation of 
trimethylamine (TMA) (7), derived largely from carnitine and choline through gut microbial 
metabolism. These substrates are found in red meat and eggs which are representative of a 
Western diet. Therefore, TMAO levels could be used to monitor the effect of dietary 
intervention, particularly for the consumption of a Western diet. In this study, we examined the 
effect of acute choline loading on TMAO levels in healthy adult volunteers.  
 Eighteen healthy omnivorous adult volunteers, with no history of recent use of 
antibiotics/probiotics, completed this study. Baseline characteristics and blood samples were 
obtained from participants at baseline (BL). Participants were asked to complete a daily written 
food diary and returned after 2 weeks (visit 2, V2).  The consumption of red meat, fish, and 
eggs was not permitted 24 hours before BL and V2. Prior to taking 700 mg of choline bitartrate 
capsules (Solgar, USA), a blood sample was collected to measure TMAO level at time zero 
(0), then at 2, 4, 6 and 8 hours post choline consumption. During V2, participants were given 
a standardised low-choline breakfast and lunch (total choline intake <50 mg) (8), between 0-2 
and 4-6 hours respectively. This protocol was approved by the local ethics committee and 
adhered to the Declaration of Helsinki. All participants provided written informed consent. 
Plasma samples were quantified in duplicate for TMAO, using stable isotope dilution liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) on a Shimadzu LC-30AD coupled 
with an 8050 triple quadruple mass spectrometer (TQ-MS), using an optimised version of a 
previously described method (9), with a run time of 1 minute and limit of quantification (LOQ) 
of 0.1 μmol/L. Individual responses of circulating TMAO levels in participants are shown in 
Figure 1a.  
  
Participants showed a range in circulating TMAO levels between 0-20 μmol/L over the 
8 hour period, with a few (n=4) showing higher TMAO levels following six hours post-choline 
consumption (>20 μmol/L).  We observed that there were patients that showed raised TMAO 
levels in response to choline loading (‘responders’) and those that did not (‘non-responders’). 
To further investigate the different responses to choline loading (response vs non-response), 
participants were split according to the median baseline TMAO level of 2.0 μmol/L (Figure 
1b), into high TMAO (HT) and low TMAO (LT) groups. TMAO levels rapidly and 
significantly increased from 4 hours after choline loading in the HT group; in contrast, TMAO 
levels showed no change at any time point after choline loading in the LT group (Figure 1b) 
(p=0.012). TMAO levels in the HT group were higher than those in the LT group at all times 
during the acute oral choline challenge (3.1-16.3 μmol/L vs. 1.3-3.3 μmol/L, respectively). 
Participants in the HT group (n=9) tended to be older and had higher alcohol intake compared 
to those in the LT group (n=9); however this was not statistically significant (p=0.094 and 
p=0.063, respectively). Gender, ethnicity, BMI, and weekly physical activity were similar 
between groups (p>0.05). Dietary records from the two weeks prior to acute choline loading 
as well as baseline records did not show any differences in TMA rich food intake (red meat, 
eggs or fish) between groups (Table 1). No side effects (e.g. fishy body odour) were reported 
during the study. 
 The present study indicates that acute choline loading in healthy subjects produces a 
differential response in circulating TMAO levels (i.e. ‘responders’ and ‘non-responders’). 
These two different response groups in TMAO production following choline challenge were 
demonstrated for the first time by the present study. To note, individuals with a ‘responder’ 
phenotype had higher baseline TMAO levels. Furthermore, food diaries from these individuals, 
assessed to determine protein intake in the two weeks before choline loading, showed no 
significant differences in TMA rich foods (e.g. red meat, eggs) compared to those with a ‘non-
  
responder’ phenotype. This indicates that omnivorous individuals can have different responses 
to dietary sources of choline, independently of daily dietary conditions. TMAO levels were 
also analysed for association with participants’ physical activity due to the beneficial effect of 
physical activity on cardiovascular risk, in particular when combined with dietary intervention 
(10).  We did not observe differences in TMAO levels with respect to physical activity between 
the low and high TMAO groups. In previous studies, acute dietary supplementation of choline 
has been shown to increase TMAO levels in a general population (11). However, most studies 
have focused on carnitine, demonstrating the effect of L-carnitine supplementation with 
increased TMAO levels correlated to chronic carnitine intake (12). TMAO levels have been 
attributed more to carnitine rather than choline and from red meat rather than other sources of 
protein (13). Whilst these studies showed that TMAO levels are significantly increased with 
L-carnitine and red meat intake, they did not account for baseline differences in the TMAO 
levels of participants and whether these could affect subsequent TMAO increase, underlying a 
responder or non-responder phenotype. Further, single TMAO time point cross-sectional 
studies are unable to ascertain whether there are temporal or individual differences in TMAO 
production, following dietary/loading challenge (e.g. response). The current study sheds light 
upon the hypothesis that individuals respond differently to dietary choline intake, which could 
be related to reduced FMO3 activity or gut bacterial conversion of choline to TMA, resulting 
in inefficient conversion of choline to TMAO. Further investigation of gut microbial 
composition and FMO3 activity to identify outstanding factors for response to choline loading 
is warranted.  
In conclusion, our findings suggest the presence of different TMAO responses to acute 
choline loading. As a current goal of cardiovascular disease prevention is to target lifestyle 
factors (14), with dietary manipulation (e.g. to reduce red meat consumption) being one of the 
mainstays for intervention, the finding that not all subjects respond uniformly to dietary choline 
  
intake, and the use of a loading test to identify ‘responders/non-responders’ might help to 
further stratify patients into appropriate dietary interventions. Further studies that address 
whether the ‘responder’ phenotype affords a higher risk for cardiovascular risk, and can be 
used to identify patients warranting dietary intervention are needed. 
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Table 1. Demographics data from the participants assessed for this study.  
  Total low TMAO high TMAO  
  (n=18) (≤2.0 µmol/L) (>2.0 µmol/L) p value 
Demographics     
Age 28 [23-36] 25 [21-29] 33 [27-49] 0.094 
Male 5 (28%) 1 (11%) 4 (44%) 0.294 
Caucasian 14 (78%) 7 (78%) 7 (78%) 1.000 
BMI 21.7 [20.9-23.8] 20.9 [20.2-23.8] 22.6 [21.5-23.7] 0.258 
Current smoker 1 (6%) 0 (0%) 1 (11%) 1.000 
FH of CVD 3 (17%) 2 (22%) 1 (11%) 1.000 
Systolic blood pressure 
(mmHg) 
117 [110-129] 118 [110-124] 116 [115-133] 0.666 
Diastolic blood 
pressure (mmHg) 
78 [74-86] 78 [70-86] 77 [76-82] 0.863 
Heart rate (beats/min) 68 [63-78] 65 [65-76] 70 [62-78] 0.605 
Physical Activity 
(days/week) 
3.5 [2.5-7] 4.0 [2.5-7] 3.0 [3-7] 0.876 
Intake history     
    Alcohol 
(units/week) 
1 [0-3] 0 [0-0.1] 2 [1-6] 0.063 
Red meat (units/week) 3 [1-4] 2 [1-3] 3 [3-4] 0.258 
Fish (units/week) 1 [1-3] 1 [0.1-3] 2 [1-2] 0.489 
Eggs (units/week) 1 [1-3] 1 [1-2] 2 [1-4] 0.297 
Laboratory      
    Cholesterol (g/dL) 4.7 [4.0-5.2] 4.6 [4.4-5.2] 4.7 [3.9-5.2] 0.796 
    HDL (g/dL) 1.6 [1.4-1.9] 1.5 [1.4-1.7] 1.9 [1.4-2.0] 0.546 
TMAO (µmol/L)     
  Baseline 2.0 [1.3-4.0] 1.3 [0.7-1.6] 4.0 [3.3-5.9] <0.001* 
  After choline loading     
     0 hour 2.1 [1.4-3.4] 1.5 [1.3-1.9] 3.4 [2.2-3.5] 0.024* 
     2 hours 2.0 [1.3-3.1] 1.3 [1.2-2.0] 3.1 [2.0-4.0] 0.021* 
     4 hours 1.9 [1.2-4.5] 1.3 [1.1-1.8] 4.5 [2.7-6.5] 0.001* 
     6 hours 4.1 [1.0-10.3] 1.0 [0.8-1.9] 10.3 [7.3-34.0] 0.001* 
     8 hours 6.6 [4.4-16.3] 3.3 [1.0-6.2] 16.3 [11.6-50.5] 0.001* 
Analysed data were split into high and low TMAO groups (HT and LT groups respectively), 
based on the median of baseline values. Mann-Whitney U test for continuous variables and 
chi-squared test for categorical variables were used to examine between-group differences. 
Subsequent analyses used a general linear model with repeated measures and Bonferroni 
correction to compare group TMAO means during the oral acute choline challenge. P values 
<0.05 were deemed statistically significant. IBM SPSS Statistics (v25, IBM Corp., Armonk, 
NY, USA) and Prism (v.7, GraphPad) were used.  
BMI: Body mass index; FH: familiar history; CVD: cardiovascular diseases; TMAO: 
trimethylamine N-oxide; HDL: high density lipoprotein. * P< 0.05  
  
Figure 1. (a) Plasma TMAO levels over an 8 hour period following acute choline loading of 
700 mg orally after 0 hours (arrow). (b) Participants were split into two groups dependent on 
the median TMAO levels at baseline (high or low TMAO).  
 
Data are presented as the mean ± SEM. NS: non-significant. * P<0.05 
